Good But Could Be Better: Industry On EMA Proposals For Improving Early Access Schemes
This article was originally published in SRA
Executive Summary
Improvements proposed by the European Medicines Agency to its conditional marketing authorization (CMA) pathway are good but would be better if, for instance, they also allowed medicines submitted via the CMA route to automatically qualify for accelerated assessment, according to industry.